Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06609369 · ClinicalTrials.gov registry record · Phase 2
Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse
A Phase 2 study of Insomnia and Tobacco Use, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
- 2
- Study locations
NCT06609369: Recruiting Phase 2 study of Insomnia and Tobacco Use, sponsored by Yale University.
NCT06609369 is a Phase 2 study of Insomnia and Tobacco Use that is actively recruiting participants, run by Yale University. The registered enrollment target is 114 participants, below the 169-participant average among 151 other Insomnia trials with a reported enrollment target (33% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06609369, a Phase 2 study of Insomnia and Tobacco Use, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study aims to investigate whether behavioral interventions promote cessation in adult smokers by ameliorating negative emotions and improving self-control and identify the neural markers of these effects.
Primary Outcome
Mean number cigarettes smoked per day assessed by Time Line Follow Back method
Conditions Studied
Interventions
- BEHAVIORAL Experimental health intervention
- DRUG Varenicline
Study Locations (2)
Connecticut
- Connecticut Mental Health Center - New Haven
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2025-04-21 |
| Est. Completion | 2029-06 |
| Phase | Phase 2 |
What NCT06609369 shows while recruiting
NCT06609369 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 169-participant average among 151 other Insomnia trials with a reported enrollment target (33% lower).
The record links to 3 conditions, with Insomnia appearing as the primary indexed condition, and to 2 interventions - of which Experimental health intervention is the first listed.
NCT06609369 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06609369 about?
NCT06609369 is a clinical study titled "Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse". The study aims to investigate whether behavioral interventions promote cessation in adult smokers by ameliorating negative emotions and improving self-control and identify the neural markers of these effects.
What is the current status of trial NCT06609369?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2025-04-21. Estimated completion is 2029-06.
What conditions does trial NCT06609369 study?
This clinical trial studies the following conditions: Insomnia, Tobacco Use, Tobacco Cessation.
What interventions are being tested in trial NCT06609369?
The interventions under investigation include: Experimental health intervention (BEHAVIORAL), Varenicline (DRUG).
Who is sponsoring clinical trial NCT06609369?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06609369 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06609369's enrollment target sits among peer trials
114 57th of 151 higher than 94 of 151 other Insomnia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insomnia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Pimavanserin for Insomnia in Veterans With PTSD
RECRUITING · Phase 2
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
-
Suvorexant for Treatment of AUD and PTSD
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
-
Resilience Enhancement Following Sleep Treatment
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI